Related references
Note: Only part of the references are listed.WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases
Helio S. Soder et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective
S-M Huang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal Impairment
R. L. Lalonde et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Cefepime: a reappraisal in an era of increasing antimicrobial resistance
Andrea Endimiani et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2008)